Human VCAM‑1/CD106 Antibody

Detection of Human VCAM‑1/CD106 by Simple Western^TM.

Simple Western lane view shows lysates of HUVEC human umbilical vein endothelial cells untreated (-) or treated (+) with 10 ng/ml Recombinant Human TNF‑ alpha (210-TA) for 24 hrs, loaded at 0.2 mg/mL. A specific band was detected for VCAM‑1/CD106 at approximately 132 kDa (as indicated) using 20 µg/mL of Goat Anti-Human VCAM‑1/CD106 Polyclonal Antibody (Catalog # BBA19). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

Detection of VCAM-1/CD106 by Western Blot

IL‐1 beta stimulation increases endothelial glucose uptake, glycolysis, and PFKFB3 expression. (A) Uptake of 14C‐2‐deoxy‐d‐glucose in IL‐1 beta ‐stimulated HUVECs (1 ng·mL−1, 16 h; mean ± SD; n = 3 donors). (B) Rate of glycolysis in IL‐1 beta ‐stimulated HUVECs (n = 3 donors). (C) Glycolysis fold change 6 h after stimulation with different doses of IL‐1 beta (n = 3 donors). (D) RT‐qPCR of PFKFB3 following in IL‐1 beta ‐stimulated HUVECs (1 ng·mL−1) (n = 3 donors). (E) Representative immunoblot for PFKFB3 (top), VCAM‐1 (middle) and beta ‐tubulin loading control (bottom) in IL‐1 beta ‐stimulated HUVECs (1 ng·mL−1, 2–24 h). (F) Densitometric quantification of PFKFB3 relative to beta ‐tubulin loading control (n = 5 donors). (G) RT‐qPCR of VCAM‐1 in IL‐1 beta ‐stimulated HUVECs (1 ng·mL−1, 2–24 h) (n = 3 donors). (H) Densitometric quantification of VCAM‐1 relative to beta ‐tubulin loading control (n = 5 donors). B–D and F–H: lines show means, and dots show individual donors. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33979025), licensed under a CC-BY license. Not internally tested by R&D Systems.